KLRK1 and neoplasm: In this study, they acquire NK cells from the MAs of OC patients that upregulated the surface expression of activating receptors (NKG2D, NKp30, NKp44), producing anti-tumor cytokines in the presence of OC cells and mediating direct tumor cytotoxicity against ascites-derived, primary OC cells obtained from autologous patients.